Partner Fund Management, L.P. Buys Biogen Inc, Anthem Inc, Centene Corp, Sells Novo Nordisk A/S, Biomarin Pharmaceutical Inc, Penumbra Inc

• New Purchases: BIIB, ANTM, CNC, PFE, IMMU, ICUI, HUM, ABT, UNH, NVST, EXAS, MOR, ABBV, VRTX, AMRN, HALO, NVDA, SQ,
• Added Positions: NVRO, KRTX, AERI, AXNX, FLDM, PYPL,
• Reduced Positions: BMRN, PEN, ZBH, NXPI, MCHP, ARNA, IRTC, INTU, CRM, CTLT, ALXN, MOH, EW, GILD, BOLD, AGN, MSFT, NVS, COUP, CI, IQV, HCA, VC, DERM, CSII, ICLR, BABA, CHRS, ACOR, ELGX,
• Sold Out: NONOF, WCG, DXCM, MYOK, TWLO, PTCT, SAGE, GDDY, WDC, QURE, SYK, PBYI, MRTX, MKSI, AMD, V, INSP, VYGR, TWTR, PRNB, FATE, LYV, AVRO, GS, DLPH, EIDX, TW, ALNA, LVGO, AMK,

For the details of Partner Fund Management, L.P.'s stock buys and sells, go to https://www.gurufocus.com/guru/partner+fund+management%2C+l.p./current-portfolio/portfolio

1. Gilead Sciences Inc (GILD) - 3,024,200 shares, 9.58% of the total portfolio.
2. Alexion Pharmaceuticals Inc (ALXN) - 1,076,442 shares, 5.68% of the total portfolio. Shares reduced by 25.59%
3. Cigna Corp (CI) - 519,500 shares, 5.18% of the total portfolio.
4. Gilead Sciences Inc (GILD) - 1,351,736 shares, 4.28% of the total portfolio. Shares reduced by 26.69%
5. Audentes Therapeutics Inc (BOLD) - 1,232,873 shares, 3.60% of the total portfolio. Shares reduced by 46.77%

Partner Fund Management, L.P. initiated holding in Biogen Inc. The purchase prices were between $220.06 and $304.07, with an estimated average price of $279.04. The stock is now traded at around $333.00. The impact to a portfolio due to this purchase was 3.3%. The holding were 228,328 shares as of .

Partner Fund Management, L.P. initiated holding in Anthem Inc. The purchase prices were between $234.82 and $306.42, with an estimated average price of $276.42. The stock is now traded at around $297.82. The impact to a portfolio due to this purchase was 2.92%. The holding were 198,548 shares as of .

Partner Fund Management, L.P. initiated holding in Centene Corp. The purchase prices were between $42.73 and $63.65, with an estimated average price of $54.66. The stock is now traded at around $64.94. The impact to a portfolio due to this purchase was 2.51%. The holding were 819,229 shares as of .

Partner Fund Management, L.P. initiated holding in Pfizer Inc. The purchase prices were between $34.7 and $39.38, with an estimated average price of $37.62. The stock is now traded at around $36.51. The impact to a portfolio due to this purchase was 1.76%. The holding were 923,126 shares as of .

Partner Fund Management, L.P. initiated holding in Immunomedics Inc. The purchase prices were between $13.54 and $21.77, with an estimated average price of $17.78. The stock is now traded at around $18.36. The impact to a portfolio due to this purchase was 1.55%. The holding were 1,499,239 shares as of .

Partner Fund Management, L.P. initiated holding in ICU Medical Inc. The purchase prices were between $151.88 and $189.51, with an estimated average price of $172.62. The stock is now traded at around $214.00. The impact to a portfolio due to this purchase was 1.51%. The holding were 165,665 shares as of .

Partner Fund Management, L.P. added to a holding in Nevro Corp by 45.65%. The purchase prices were between $76.41 and $117.54, with an estimated average price of $99.76. The stock is now traded at around $139.66. The impact to a portfolio due to this purchase was 1.04%. The holding were 577,163 shares as of .

Partner Fund Management, L.P. added to a holding in Karuna Therapeutics Inc by 46.73%. The purchase prices were between $11.44 and $123.99, with an estimated average price of $45.23. The stock is now traded at around $99.72. The impact to a portfolio due to this purchase was 0.7%. The holding were 602,551 shares as of .

Partner Fund Management, L.P. added to a holding in Aerie Pharmaceuticals Inc by 31.82%. The purchase prices were between $17.72 and $25.1, with an estimated average price of $20.77. The stock is now traded at around $19.45. The impact to a portfolio due to this purchase was 0.69%. The holding were 2,413,464 shares as of .

Partner Fund Management, L.P. added to a holding in Axonics Modulation Technologies Inc by 118.73%. The purchase prices were between $19.57 and $28.96, with an estimated average price of $23.9. The stock is now traded at around $34.29. The impact to a portfolio due to this purchase was 0.4%. The holding were 550,026 shares as of .

Partner Fund Management, L.P. added to a holding in PayPal Holdings Inc by 25.20%. The purchase prices were between $96.64 and $109.75, with an estimated average price of $104.36. The stock is now traded at around $122.99. The impact to a portfolio due to this purchase was 0.02%. The holding were 19,076 shares as of .

Partner Fund Management, L.P. sold out a holding in Novo Nordisk A/S. The sale prices were between $49.02 and $58.34, with an estimated average price of $55.11.

Partner Fund Management, L.P. sold out a holding in WellCare Health Plans Inc. The sale prices were between $258.37 and $332.8, with an estimated average price of $301.65.

Partner Fund Management, L.P. sold out a holding in DexCom Inc. The sale prices were between $146.46 and $229.18, with an estimated average price of $191.34.

Partner Fund Management, L.P. sold out a holding in MyoKardia Inc. The sale prices were between $50.92 and $74.6, with an estimated average price of $61.06.

Partner Fund Management, L.P. sold out a holding in Twilio Inc. The sale prices were between $91.06 and $116.59, with an estimated average price of $102.

Partner Fund Management, L.P. sold out a holding in PTC Therapeutics Inc. The sale prices were between $33.65 and $50.07, with an estimated average price of $42.83.